Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2'-dimethyl-4-aminobiphenyl

Toxicology and Applied Pharmacology

Volumn 157, Issue 1, 1999, Pages 36-42

  Feng, Yi ^a,c   Finley, John W ^b   Davis, Cindy D ^b   Becker, William K ^a   Fretland, Adrian J ^c   Hein, David W ^a,c  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Grand Forks Hum Nutr Res Center   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

3,2' dimethyl 4 aminobiphenyl; Aberrant crypt foci; Aromatic amines; Colorectal cancer; Selenium

Indexed keywords

2',3 DIMETHYL 4 BIPHENYLAMINE; AROMATIC AMINE; SELENIUM;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; GLUCURONIDATION; INTESTINE CRYPT; NONHUMAN; NUTRITIONAL DEFICIENCY; RAT;

ANIMALIA; ARACHIS HYPOGAEA; PICHIA JADINII; RODENTIA; TORULA;

EID: 0033563128     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8623     Document Type: Article

References (66)

1. American Cancer Society, 1997, Cancer Facts & Figures, American Cancer Society, Atlanta, GA.
2. Beland F. A., Kadlubar F. F. Formation and persistence of arylamine DNA adductsin vivo. Environ. Health Perspect. 62:1985;19-30.
3. Bird R. P. Observation and quantitation of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 37:1987;147-151.
4. Blot W. J., Li J. Y., Taylor P. R. Nutrition intervention trials in Linxian, China. J. Natl. Cancer Inst. 85:1993;1483-1492.
5. Bonelli L., Camoriano A., Ravelli P., Missale G., Bruzzi P., Aste H. Reduction of the incidence of metachronous adenomas of the large bowel by means of antioxidants: A double blind randomized trial. Sixth International Symposium on the Uses of Selenium and Tellurium. 1998.
6. PAON. Proc. Natl. Acad. Sci. USA. 86:1989;7696-7700.
7. Clark L. The epidemiology of selenium and cancer. Fed. Proc. 44:1985;2584-2589.
8. Clark L. C., Cantor K. P., Allaway W. H. Selenium in forage corps and cancer mortality in US counties. Arch. Environ. Health. 46:1991;37-42.
9. Clark L. C., Combs G. F., Turnball B. W., Slate E. H., Chalker D. K., Chow J., Davis L. S., Glover R. A., Graham G. F., Gross E. G., Krongrad A., Lesher J. L., Park H. K., Sanders B. B., Smith C. L., Taylor J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J. Am. Med. Assoc. 276:1996;1957-1963.
10. Davis C. D., Feng Y., Hein D. W., Finley J. W. The chemical form of selenium influences 3,2′-dimethyl-4-aminobiphenyl-DNA adduct formation in the rat colon. J. Nutr. 129:1999;63-69.
11. El-Bayoumy K. The role of selenium in cancer prevention. Cancer Principles and Practice of Oncology. 1991;J.B. Lippincott, Philadelphia. p. 1-15.
12. El-Bayoumy K., Chae Y. H., Upadhyaya P., Meschter C., Cohen L. A., Reddy B. S. Inhibition of 7,12-dimethylbenz(a. Cancer Res. 52:1992;2402-2407.
13. El-Bayoumy K., Upadhyaya P., Chae Y.-H., Sohn O. S., Rao C. V., Fiala E., Reddy B. S. Chemoprevention of cancer by organoselenium compounds. J. Cell. Biochem. Suppl. 22:1995;92-100.
14. Feng Y., Wagner R. J., Fretland A. J., Becker W. K., Cooley A. M., Pretlow T. P., Lee K. J., Hein D. W. Acetylator genotype (NAT2)-dependent formation of aberrant crypts in congenic Syrian hamsters administered 3,2′-dimethyl-4-aminobiphenyl. Cancer Res. 56:1996;527-531.
15. Feng Y., Fretland A. J., Rustan T. D., Jiang W., Becker W. K., Hein D. W. Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2′-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol. 147:1997;56-62.
16. Fiala E. S., Weisburger J. H., Katayama S., Chandrasekaran V., Williams G. M. Effect of disulfiram on the carcinogenicity of 3,2′-dimethyl-4-aminobiphenyl in Syrian golden hamsters and rats. Carcinogenesis. 2:1981;965-969.
17. Finley J., Matthys L., Schuler T., Korynata E. Selenium content of foods purchased in North Dakota. Nutr. Res. 16:1996;723-728.
18. Flammang T. J., Westra J. G., Kadlubar F. F., Beland F. A. DNA adducts formed from the probable proximate carcinogenNS. Carcinogenesis. 6:1985;251-258.
19. Garland M., Morris J. S., Stampfer M. J., Colditz G. A., Spate V. L., Baskett C. K., Rosner B., Speizer F. E., Willett W. C., Hunter D. J. Prospective study of toenail selenium and cancer among women. J. Natl. Cancer Inst. 87:1995;497-505.
20. Hein D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochem. Biophys. Acta. 948:1988;37-66.
21. Hein D. W., Doll M. A., Gray K., Rustan T. D., Ferguson R. J. Metabolic activation ofNNNN. Cancer Res. 53:1993;509-514.
22. Ip C. Differential effect of dietary methionine on the biopotency of selenomethionine and selenite in cancer chemoprevention. J. Natl. Cancer Inst. 80:1988;258-262.
23. Ip C., El-Bayoumy K., Upadhayaya P., Ganther H., Vadhanavikit S., Thompson H. Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemo prevention. Carcinogenesis. 15:1994;187-192.
24. Ip C., Ganther H. E. Activity of methylated forms of selenium in cancer prevention. Cancer Res. 50:1990;1206-1211.
25. Ip C., Hayes C. Tissue selenium levels in selenium-supplemented rats and their relevance in mammary cancer protection. Carcinogenesis. 10:1989;921-925.
26. Ip C., Hayes C., Budnick R. M., Ganther H. E. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res. 51:1991;595-600.
27. Ip C., Lisk D.J. Efficacy of cancer prevention by high-selenium garlic is primarily dependent on the action of selenium. Carcinogenesis. 16:1995;2649-2652.
28. Ip C., Lisk D. J., Thompson H. J. Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis. 17:1996;1979-1982.
29. Ip C., Vadhanavikit S., Ganther H. Cancer chemoprevention by aliphatic selenocyanates: Effect of chain length on inhibition of mammary tumors and DMBA adducts. Carcinogenesis. 16:1995;35-38.
30. Ito N., Hasegawa R., Sano M., Tamano S., Esumi H., Takayama S., Sugimura T. A new colon and mammary carcinogen in cooked food 2-amino-1-methyl-6-phenylimidazo [4,5-6] pyridine (PhIP). Carcinogenesis. 12:1991;1503-1506.
31. Jen J., Powell S. M., Papadopoulos N., Smith K. J., Hamilton S. R., Vogelstein B., Kinzler K. W. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:1994;5523-5526.
32. King, C. M. Romano, L. J. Schuetzle, D. 1988, Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes, Elsevier, New York.
33. Konstantakos A. K., Siu I. M., Pretlow T. G., Stellato T. A., Pretlow T. P. Human aberrant crypt foci with carcinomain situ. Gastroenterology. 111:1996;772-777.
34. Lang N. P., Butler M. A., Massengell J., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev. 3:1994;675-682.
35. Lang N. P., Kadlubar F. F. Aromatic and heterocyclic amine metabolism and phenotyping in humans. Glenhill B., Mauro F. New Horizons in Biological Dosimetry. 1991;37-47 Wiley-Liss, New York.
36. Layton D. W., Bogen K. T., Knize M. G., Hatch F. T., Johnson V. M., Felton J. S. Cancer risk of heterocyclic amines in cooked foods: An analysis and implications for research. Carcinogenesis. 16:1995;39-52.
37. Liu J., Gilbert K., Parker H. M., Haschet W. M., Milner J. A. Inhibition of 7,12-dimethylbenz[a. Cancer Res. 51:1991;4613-4617.
38. Lu J., Jiang C., Kaeck M., Ganther H., Vadhanavikit S., Ip C., Thompson H. Dissociation of the genotoxic and growth inhibiting effects of selenium. Biochem. Pharmacol. 50:1995;213-219.
39. Marshall M. V., Arnott M. S., Jacobs M. M., Griffin A. C. Selenium effects on the carcinogenicity and metabolism of 2-acetylaminofluorene. Cancer Lett. 7:1979;331-338.
40. McLellan E. A., Bird R. P. Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res. 48:1988;6187-6192.
41. Nutrient Requirements of Laboratory Animals. 1995;National Academy Press, Washington. p. 27-37.
42. Nayini J., Sugie S., El-Bayoumy K., Cohen L. A., Reddy B. S. Chemoprevention of experimental mammary carcinogenesis by the synthetic organoselenium compound, benzylselenocyanate, in rats. Carcinogenesis. 10:1989;509-512.
43. Nayini J. R., Sugie S., El-Bayoumy K., Rao C. V., Rigotty J., Sohn D. S., Reddy B. S. Effect of dietary benzylselenocyanate on azoxymethane-induced colon carcinogenesis in male F-344 rats. Nutr. Cancer. 15:1991;129-131.
44. Nussbaum M., Fiala E. S., Kulkarni B., El-Bayoumy K., Weisburger J. H. In vivo. Environ. Health Perspect. 49:1983;223-231.
45. Paglia D., Valentine W. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1967;158-169.
46. Pretlow T. P. Alterations associated with early neoplasia in the colon. Pretlow T. G., Pretlow T. P. Biochemical and Molecular Aspects of Selected Cancers. 1994;93-141 Academic Press, San Diego.
47. Pretlow T. P., Barrow B. J., Ashton W. S., O'Riordan M. A., Pretlow T. G., Turcisek J. A., Stellato T. A. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res. 56:1991;1564-1567.
48. Pretlow T. P., Brasitus T. A., Fulton N. C., Chever C., Kaplan E. L. K-ras. J. Natl. Cancer Inst. 85:1993;2004-2007.
49. Pretlow T. P., Roukhadze E. V., O'Riordan M. A., Chen J. C., Amini S. B., Stellato T. A. Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology. 107:1994;1719-1725.
50. Reddy B. S., Upadhyaya P., Simi B., Rao C. V. Evaluation of organoselenium compounds for potential chemopreventive properties in colon carcinogenesis. Anticancer Res. 14:1994;2509-2514.
51. Reddy B. S., Wynn T. T., El-Bayoumy K., Upadhyaya P., Fiala E., Rao C. V. Evaluation of organoselenium compounds for potential chemo preventative properties in colon cancer. Anticancer Res. 16:1996;1123-1128.
52. Roncucci L., Medline A., Bruce W. R. Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol. Biomarkers Prev. 1:1991;57-60.
53. Shamberger R. J., Frost D. V. Possible protective effect of selenium against human cancer. Can. Med. Assoc. J. 100:1969;682.
54. Shirai T., Nakamura A., Fukushima S., Yamamoto A., Tada M., Ito N. Different carcinogenic responses in a variety of organs, including the prostate, of five different rat stains given 3,2′-dimethyl-4-aminobiphenyl. Carcinogenesis. 11:1990;793-797.
55. Shivapurkar N., Tang Z., Ferreira A., Zasim S., Garett C., Alabaster O. Sequential analysis of K-ras. Carcinogenesis. 15:1994;775-778.
56. Smith A. J., Stern H. S., Penner M., Hay K., Mitri A., Bapat B. V., Gallinger S. Somatic APC and K-ras. Cancer Res. 54:1994;5527-5530.
57. Stampfer M., Colditz G., Willett W. The epidemiology of selenium and cancer. Cancer Surv. 6:1987;623-631.
58. Stopera S. A., Bird R. P. Expression ofras. Carcinogenesis. 13:1992;1863-1868.
59. Stopera S. A., Davie J. R., Bird R. P. Clonic aberrant crypt foci are associated with increased expression ofc-fos:c-fos. Carcinogenesis. 13:1992;573-578.
60. Thompson H. J., Meeker L. D., Kokoska S. Effect of an inorganic and organic form of dietary selenium on the promotional stage of mammary carcinogenesis in the rat. Cancer Res. 44:1984;2803-2806.
61. Tudek B., Bird R. P., Bruce W. R. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with food. Cancer Res. 49:1989;1236-1240.
62. van den Brandt P. A., Goldbohm R. A., van't Veer P., Bode P., Dorant E., Hermus R. J., Sturmans F. A prospective cohort study of toenail selenium levels and risk of gastrointestinal cancer. J. Natl. Cancer Inst. 85:1993;224-229.
63. Weisburger J. H., Fiala E. S. Experimental colon carcinogens and their role of action. Autrup H., Williams G. M. Experimental Colon Carcinogenesis. 1979;27-50 CRC Press, Boca Raton.
64. Westra J. G., Flammang T. J., Fullerton N. F., Beland F. A., Weis C. C., Kadluber F. F. Formation of DNA adductsin vivo. Carcinogenesis. 6:1985;991-1003.
65. Yamashita N., Minamoto T., Ochiai A., Onda M., Esumi H. Frequent and characteristic K-ras. Gastroenterology. 108:1995;434-440.
66. Zaidi N. H., Pretlow T. P., O'Riordan M. A., Dumenco L. L., Allay E., Gerson S. L. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras. Carcinogenesis. 16:1995;451-456.